In addition, depletion of CKAP2L increased the sensitivity of non-small cell lung cancer (NSCLC) cells to alvocidib, a pan CDK inhibitor, leading to a significant reduction of cell proliferation and an increase in cell death [9]. This evidence concerns the gene CKAP2L and non-small cell lung carcinoma.